Showing results (321-330 of 776) with videos related to

Sort By:
Pageof 78
Thrombosis and Haemostasis|August 13, 1990
Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PAH R Lijnen, B Van Hoef, F De Cock, et al.
The Journal of Laboratory and Clinical Medicine|February 1, 1983
Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assayD C Rijken, I Juhan-Vague, F de Cock, et al.
Journal of Cardiovascular Pharmacology|April 1, 1988
Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosisP Cambier, F van de Werf, G R Larsen, et al.
The Journal of Biological Chemistry|October 25, 1988
Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activatorL Hansen, Y Blue, K Barone, et al.
European Journal of Biochemistry|January 1, 1982
Messenger RNA for human tissue plasminogen activatorG Opdenakker, H Weening, D Collen, et al.
The Journal of Biological Chemistry|June 15, 1992
Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activatorP J Declerck, M De Mol, D E Vaughan, et al.
Blood|July 1, 1991
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism modelH R Lu, H R Lijnen, J M Stassen, et al.
The Journal of Biological Chemistry|January 15, 1991
Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. Effect of active site mutagenized tissue-type plasminogen activatorK Bartha, P J Declerck, H Moreau, et al.
Drugs|September 1, 1989
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agentD Collen, H R Lijnen, P A Todd, et al.
The Journal of Clinical Investigation|August 1, 1989
Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbitsD E Vaughan, P J Declerck, M De Mol, et al.
Pageof 78